Eton Pharmaceuticals Inc (ETON)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $1.84B
Last updated: Nov 17, 2026 at 11:05 AM ET
Eton Pharmaceuticals Inc (ETON) Earnings: Report Dates and Results
Eton Pharmaceuticals (ETON) is expected to report earnings on Mar 17, 2027. In the quarter ended Sep 30, 2026, Eton Pharmaceuticals reported EPS of $1.06, above the $0.34 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
ETON has an expected report date of Mar 17, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 126.3% above the $0.19 reported for the quarter ended Dec 31, 2025.
ETON Earnings Call
The latest ETON earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 30 quarters below that had an estimate, ETON beat 14, missed 14 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $57.92M, up 157.9% from $22.46M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $1.06 | $0.34 | $0.32 - $0.42 | +211.76% | Beat | +2550.0% | 2 | N/A | Nov 5, 2026 | $57.92M |
| Jun 30, 2026 | $0.35 | $0.11 | N/A | +218.18% | Beat | N/A | 2 | 0 up, 1 down | Aug 13, 2026 | $37.59M |
| Mar 31, 2026 | $0.14 | $0.14 | $0.14 - $0.14 | 0.00% | In line | N/A | 1 | 0 up, 1 down | May 14, 2026 | $24.27M |
| Dec 31, 2025 | $0.19 | $0.18 | N/A | +5.56% | Beat | N/A | 1 | 1 up, 0 down | Mar 19, 2026 | $21.28M |
| Sep 30, 2025 | $0.04 | $0.16 | $0.16 - $0.16 | -75.00% | Miss | +100.0% | 1 | 1 up, 0 down | Nov 6, 2025 | $22.46M |
| Jun 30, 2025 | -$0.10 | -$0.01 | -$0.01 - $0.08 | -900.00% | Miss | N/A | 3 | 1 up, 0 down | Aug 7, 2025 | $18.93M |
| Mar 31, 2025 | -$0.06 | $0.05 | -$0.01 - $0.13 | -220.00% | Miss | N/A | 3 | 1 up, 0 down | May 13, 2025 | $17.28M |
| Dec 31, 2024 | -$0.02 | $0.00 | N/A | -506.06% | Miss | N/A | 2 | 0 up, 0 down | Mar 18, 2025 | $11.65M |
| Sep 30, 2024 | $0.02 | -$0.01 | -$0.01 - -$0.01 | +300.00% | Beat | N/A | 2 | 0 up, 0 down | Nov 12, 2024 | $10.32M |
| Jun 30, 2024 | -$0.12 | -$0.07 | -$0.07 - -$0.07 | -71.43% | Miss | -166.7% | 1 | 0 up, 0 down | Aug 8, 2024 | $9.07M |
| Mar 31, 2024 | -$0.03 | -$0.07 | -$0.07 - -$0.07 | +57.14% | Beat | N/A | 1 | 0 up, 0 down | May 9, 2024 | $7.97M |
| Dec 31, 2023 | -$0.09 | -$0.04 | -$0.04 - -$0.04 | -125.00% | Miss | -325.0% | 1 | 0 up, 0 down | Mar 14, 2024 | $7.31M |
| Sep 30, 2023 | -$0.02 | -$0.10 | -$0.10 - -$0.10 | +80.00% | Beat | N/A | 1 | 0 up, 0 down | Nov 9, 2023 | $7.03M |
| Jun 30, 2023 | $0.18 | -$0.09 | -$0.09 - -$0.09 | +300.00% | Beat | N/A | 1 | 0 up, 0 down | Aug 10, 2023 | $12.00M |
| Mar 31, 2023 | -$0.10 | -$0.14 | -$0.14 - -$0.14 | +28.57% | Beat | N/A | 1 | 0 up, 0 down | May 11, 2023 | $5.30M |
| Dec 31, 2022 | $0.04 | $0.01 | $0.01 - $0.01 | +300.00% | Beat | 0.0% | 1 | 0 up, 0 down | Mar 16, 2023 | $8.50M |
| Sep 30, 2022 | -$0.12 | -$0.15 | -$0.15 - -$0.15 | +20.00% | Beat | N/A | 1 | 0 up, 0 down | Nov 10, 2022 | $3.22M |
| Jun 30, 2022 | -$0.06 | $0.03 | $0.03 - $0.03 | -300.00% | Miss | N/A | 1 | 0 up, 1 down | Aug 11, 2022 | $7.36M |
| Mar 31, 2022 | -$0.21 | -$0.08 | -$0.19 - $0.03 | -162.50% | Miss | -210.5% | 2 | 0 up, 0 down | May 12, 2022 | $2.18M |
| Dec 31, 2021 | $0.04 | $0.19 | N/A | -78.95% | Miss | N/A | N/A | 0 up, 0 down | Mar 16, 2022 | $6.09M |
| Sep 30, 2021 | -$0.24 | -$0.13 | N/A | -84.62% | Miss | N/A | 1 | 1 up, 0 down | Nov 15, 2021 | $775000 |
| Jun 30, 2021 | -$0.10 | -$0.14 | -$0.20 - -$0.08 | +28.57% | Beat | N/A | 2 | N/A | Aug 16, 2021 | $3.07M |
| Mar 31, 2021 | $0.19 | $0.19 | $0.19 - $0.19 | 0.00% | In line | N/A | 2 | N/A | May 13, 2021 | $11.90M |
| Dec 31, 2020 | -$0.32 | -$0.26 | -$0.26 - -$0.26 | -23.08% | Miss | N/A | 2 | N/A | Mar 16, 2021 | $180000 |
| Sep 30, 2020 | -$0.31 | -$0.25 | -$0.32 - -$0.20 | -24.00% | Miss | N/A | 3 | N/A | Nov 12, 2020 | N/A |
| Jun 30, 2020 | -$0.23 | -$0.26 | -$0.29 - -$0.22 | +11.54% | Beat | N/A | 3 | N/A | Aug 12, 2020 | $20000 |
| Mar 31, 2020 | -$0.50 | -$0.23 | -$0.33 - -$0.14 | -117.39% | Miss | N/A | 3 | N/A | May 14, 2020 | N/A |
| Dec 31, 2019 | -$0.15 | -$0.26 | -$0.34 - -$0.21 | +42.31% | Beat | N/A | 3 | N/A | Mar 5, 2020 | $459000 |
| Sep 30, 2019 | -$0.28 | -$0.24 | -$0.28 - -$0.22 | -16.67% | Miss | N/A | 3 | N/A | Nov 14, 2019 | N/A |
| Jun 30, 2019 | -$0.18 | -$0.28 | N/A | +35.71% | Beat | N/A | 1 | N/A | Aug 6, 2019 | N/A |
| Mar 31, 2019 | -$0.42 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 7, 2019 | $500000 |
| Dec 31, 2018 | -$1.48 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 25, 2019 | N/A |
| Sep 30, 2018 | -$0.53 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 20, 2018 | N/A |
| Jun 30, 2018 | -$0.23 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 10, 2018 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.07, a profit after a loss of $0.15 per share the year before. It was -$2.24 for the year ended Dec 31, 2018, the oldest of the 8 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.07 | N/A |
| Dec 31, 2024 | -$0.15 | N/A |
| Dec 31, 2023 | -$0.03 | N/A |
| Dec 31, 2022 | -$0.35 | N/A |
| Dec 31, 2021 | -$0.11 | N/A |
| Dec 31, 2020 | -$1.36 | N/A |
| Dec 31, 2019 | -$1.03 | N/A |
| Dec 31, 2018 | -$2.24 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,600 words across 9 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,619 | 9 | |
| 2026Q2 | Jun 30, 2026 | 5,930 | 9 | |
| 2026Q1 | Mar 31, 2026 | 5,429 | 8 | |
| 2025Q4 | Dec 31, 2025 | 7,505 | 8 | |
| 2025Q3 | Sep 30, 2025 | 4,769 | 7 | |
| 2025Q2 | Jun 30, 2025 | 5,006 | 7 | |
| 2025Q1 | Mar 31, 2025 | 5,478 | 7 | |
| 2024Q4 | Dec 31, 2024 | 3,889 | 7 |
2026Q3 Earnings Call
Opening remarks
David Krempa Chief Business Officer Thank you, operator. Good afternoon, everyone, and welcome to Eton's Third Quarter 2026 Conference Call. This afternoon, we issued our earnings release, which is available on our website, etonpharma.com. Joining me today are Sean Brynjelsen, our CEO; Ipek Trinkaus, our Chief Commercial Officer; and Judy Matthews, our Chief Financial Officer. Before we begin, I would like to remind everyone that remarks made during the call may contain forward-looking statements and involve risks and uncertainties that could cause actual results to differ materially from those contained in these forward-looking statements. Please see the forward-looking statements disclaimer in our earnings release and the risk factors in the company's filings with the SEC. Now I will turn the call over to our CEO, Sean Brynjelsen.
Sean Brynjelsen CEO Thank you, David. Good afternoon, everyone, and thank you for joining us today. It was another outstanding quarter for Eton with record revenue, significant margin expansion and strong cash flow generation. We continue to fire on all cylinders on both the commercial and development fronts. Revenue grew a remarkable 158% year-over-year, reaching $57.9 million in the quarter. The third quarter was the first with a full quarter of HEMANGEOL revenue, which was a significant growth driver, but we also saw strength across all our key products. In fact, we hit record-high levels of active patient counts in the quarter on all of our key branded products, including INCRELEX, HEMANGEOL, ALKINDI SPRINKLE, KHINDIVI, GALZIN and DESMODA. At the start of 2026, we set three ambitious long-term goals for the company to help articulate to investors where we saw our business heading in the coming years. We like to set aspirational goals that push the envelope, not easy goals, and I know there was initially some skepticism about how achievable our goals were. From today's results, it's clear we are well ahead of that schedule. Our first goal was to reach a $200 million annualized revenue run rate by the end of 2027. We exited 2025 at about an $85 million run rate. So this required us to more than double our revenue within 24 months. As you saw, with nearly $58 million of revenue this quarter, we far exceeded this goal and did so an impressive five quarters ahead of schedule. Our second goal was focused on profitability, to produce a 50% adjusted EBITDA margin by 2028, up from the 20% we reported in 2025. It happened much faster. This quarter, we achieved a 49% adjusted EBITDA margin even after the expensing of our $3 million licensing payment for ASN-001, which was not adjusted out of the calculation.
Frequently Asked Questions About ETON
When is Eton Pharmaceuticals's next earnings date?
Eton Pharmaceuticals's next earnings report is expected for Mar 17, 2027.
Did ETON beat earnings estimates last quarter?
Yes. Eton Pharmaceuticals reported EPS of $1.06 for the quarter ended Sep 30, 2026, above the $0.34 estimate, a 211.76% surprise.
What EPS do analysts expect from ETON next quarter?
The consensus EPS estimate for Eton Pharmaceuticals for the quarter ending Dec 31, 2026 is $0.43 from 6 analysts, with estimates from $0.29 to $0.58.
How often does ETON beat earnings estimates?
Eton Pharmaceuticals beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -158.19%.
ETON pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors